Is Alpha Lipoic Acid Neuropathy Meta-Analysis safe?

The current Migaku evidence database contains 2 reusable source documents for Alpha Lipoic Acid Neuropathy Meta-Analysis. This answer focuses on safety, limits, and clinician-discussion contexts. - A fixed-dose combination of low-dose pregabalin and thioctic acid is non-inferior to high-dose pregabalin for analgesic efficacy and demonstrates an improved safety profile. [Zárate E (2026); evidence level 4] - High-dose pregabalin is effective for painful diabetic peripheral neuropathy, but dose-dependent adverse effects limit its use. [Zárate E (2026); evidence level 4] - Thioctic acid (alpha-lipoic acid), a mitochondrial antioxidant with neuromodulatory properties, may improve tolerability without reducing efficacy when combined with lower doses of pregabalin. [Zárate E (2026); evidence level 4] - Conclusion Roflumilast may offer superior glycemic and oxidative stress control benefits, though neuropathy symptoms control was comparable to ALA. [Elsharab A (2025); evidence level 4] - Aim We aimed to evaluate the efficacy and safety of roflumilast compared to alpha-lipoic acid (ALA) in type 2 diabetic patients with diabetic neuropathy. [Elsharab A (2025); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.